Second line chemotherapy with irinotecan (CPT-11) and mitomycin-C (MMC) in patients with advanced/metastatic colorectal (CC) and gastric cancer (GC): A phase II trial.

被引：0
|
作者：
Papamichael, D
Bamias, A
Ioannides, G
Syrigos, K
Demosthenous, C
Pavlidis, N
机构：
[1] Univ Athens, Sotiria Hosp, Dept Med 3, Athens, Greece
[2] Ioannina Univ Hosp, Ioannina, Greece
[3] BO Cyprus Oncol Ctr, Nicosia, Cyprus
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
250
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [21] EFFICACY OF COMBINATION CHEMOTHERAPY WITH IRINOTECAN (CPT-11) PLUS CAPECITABINE IN PATIENTS WITH METASTATIC OR ADVANCED COLORECTAL CARCINOMA
    Gennatas, C.
    Michalaki, V.
    Gennatas, S.
    Voros, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 148 - 148
  • [22] Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer
    Tsunoda, A.
    Yasuda, N.
    Nakao, K.
    Narita, K.
    Watanabe, M.
    Matsui, N.
    Kusano, M.
    ONCOLOGY, 2009, 77 (3-4) : 192 - 196
  • [23] Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study
    Do Hyoung Lim
    Young Suk Park
    Byeong-Bae Park
    Sang Hoon Ji
    Jeeyun Lee
    Keon Woo Park
    Jung Hoon Kang
    Se-Hoon Lee
    Joon Oh Park
    Kihyun Kim
    Won Seog Kim
    Chul Won Jung
    Young-Hyuck Im
    Won Ki Kang
    Keunchil Park
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 10 - 14
  • [24] Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study
    Lim, DH
    Park, YS
    Park, BB
    Ji, SH
    Lee, J
    Park, KW
    Kang, JH
    Lee, SH
    Park, JO
    Kim, K
    Kim, WS
    Jung, CW
    Im, YH
    Kang, WK
    Park, K
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (01) : 10 - 14
  • [25] Phase II study of irinotecan (CPT-11) in patients with advanced colorectal cancer resistant to 5-fluorouracil based chemotherapy.
    Salinas, P
    Lara, MA
    de Septién, CFM
    Feliu, J
    Espinosa, E
    de Castro, J
    García-Girón, C
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S76 - S76
  • [26] Irinotecan (CPT-11) in combination with raltitrexed (TX) in patients with previously untreated, advanced colorectal cancer (ACC) patients.: Preliminary results of a phase I/II trial.
    Losa, F
    Manzano, H
    Vicente, P
    Rifa, J
    Ocaña, J
    Balcells, M
    Mediavilla, D
    Heras, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 288S - 288S
  • [27] Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy
    García-Girón C.
    Palomo A.G.
    López C.A.
    Carbonero A.L.
    Ureña M.M.
    Cebrián E.A.
    Galíndez R.B.
    Yustos M.A.
    Gallego J.A.
    Clinical and Translational Oncology, 2005, 7 (6) : 244 - 249
  • [28] Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer
    Yamao, T
    Shirao, K
    Matsumura, Y
    Muro, K
    Yamada, Y
    Goto, M
    Chin, K
    Shimada, Y
    ANNALS OF ONCOLOGY, 2001, 12 (12) : 1729 - 1735
  • [29] Irinotecan (CPT-1 1) and mitomycin-c (MMC) as second-line therapy in advanced gastric cancer - A phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106)
    Giuliani, F
    Molica, S
    Maiello, E
    Battaglia, C
    Gebbia, V
    Di Bisceglie, M
    Vinciarelli, G
    Gebbia, N
    Colucci, G
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2005, 28 (06): : 581 - 585
  • [30] The current chemotherapy for advanced pancreatic cancer including the result of phase II study of irinotecan (CPT-11)
    Sumii, Toshihiko
    Fujimori, Nao
    Funakoshi, Akihiro
    PANCREAS, 2008, 37 (01) : 112 - 112
12345